Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Taiwan ETF (EWT) vs Heron Therapeutics Inc (HRTX) Price & Performance

iShares MSCI Taiwan ETFTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Taiwan ETF vs Heron Therapeutics Inc — how do they compare? iShares MSCI Taiwan ETF trades at $105.6, while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: iShares MSCI Taiwan ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

EWTHRTX
Sector
Broad Market / FactorHealth
52-Week High
$111.53$1.49
52-Week Low
$58.05$0.32
Market Cap
$63.41M
Enterprise Value
$161.31M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Taiwan ETF

EWT, the iShares MSCI Taiwan ETF, trades at $103.09, up 1.09% today, with a bullish technical signal driven by strong moving average alignment. Recent news highlights Taiwan's market outperformance, fueled by AI-driven semiconductor demand, with the ETF gaining over 60% year-to-date. Key support lies at $102, while resistance is at $104. The RSI_6 at 96.58 indicates overbought conditions, suggesting potential near-term consolidation.

The outlook remains positive due to Taiwan's critical role in the global semiconductor supply chain, though risks include geopolitical tensions with China and dependency on AI sector momentum. Analysts are bullish given the ETF's exposure to top performers like TSMC, but investors should monitor any shifts in foreign capital flows and semiconductor cycle dynamics.

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI Taiwan ETF

EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.

Read more on EWT

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX